Prosecution Insights
Last updated: April 19, 2026
Application No. 17/262,009

Method for the Study of Embryo Mutations in IN VITRO Reproduction Processes

Final Rejection §101
Filed
Jan 21, 2021
Examiner
SMITH, EMILIE ALINE
Art Unit
1686
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Journey Genomics S L
OA Round
4 (Final)
52%
Grant Probability
Moderate
5-6
OA Rounds
4y 8m
To Grant
87%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allow Rate
35 granted / 68 resolved
-8.5% vs TC avg
Strong +35% interview lift
Without
With
+35.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 8m
Avg Prosecution
33 currently pending
Career history
101
Total Applications
across all art units

Statute-Specific Performance

§101
28.5%
-11.5% vs TC avg
§103
27.3%
-12.7% vs TC avg
§102
13.1%
-26.9% vs TC avg
§112
22.8%
-17.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 68 resolved cases

Office Action

§101
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s Response Applicant’s response, filed 12/12/2025, has been fully considered. Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claims Status Claims 1, 3, 9, 11, and 12 are pending. Claims 1, 3, 9, 11, and 12 are examined. Withdrawn Objections/Rejections The rejection of claims 1, 3, 9, 11, and 12 under 35 USC 112(b) is withdrawn in view of the amendments submitted Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1, 3, 9, 11 and 12 are rejected under 35 U.S.C. 101 because the claimed inventions are directed to an abstract idea of mental steps, mathematic concepts, or a natural law without significantly more. Any newly recited portion is necessitated by claim amendment. The MPEP at MPEP 2106.03 sets forth steps for identifying eligible subject matter: (1) Are the claims directed to a process, machine, manufacture or composition of matter? (2A)(1) Are the claims directed to a judicially recognized exception, i.e. a law of nature, a natural phenomenon, or an abstract idea? (2A)(2) If the claims are directed to a judicial exception under Prong One, then is the judicial exception integrated into a practical application? (2B) If the claims are directed to a judicial exception and do not integrate the judicial exception, do the claims provide an inventive concept? With respect to step (1): Yes, the claims recite a method, a kit, and a computer-readable medium. With respect to step (2A)(1): The claims recite an abstract idea of mental processes and mathematic concepts. “Claims directed to nothing more than abstract ideas (such as a mathematical formula or equation), natural phenomena, and laws of nature are not eligible for patent protection” (MPEP 2106.04). Abstract ideas include mathematical concepts (mathematical formulas or equations, mathematical relationships and mathematical calculations), certain methods of organizing human activity, and mental processes (procedures for observing, evaluating, analyzing/judging and organizing information (MPEP 2106.04(a)(2)). Laws of nature or natural phenomena include naturally occurring principles/relations that are naturally occurring or that do not have markedly different characteristics compares to what occurs in nature (MPEP 2106(b). Mental processes recited in claim 1: a first SNP selection process wherein: the allele frequency values of some n candidate SNPs (t1…tk) of each subject x, wherein the subject is the family or relatives of the embryo, in a chromosomal region of interest and specifically extracted for a study population, are taken as an input; and wherein this process is configured to maximise the situation in which one of the parts has the allele frequency value of an SNP in a heterozygous state, while the other parent has the allele frequency value of an SNP in a homozygous state, and to obtain a panel of z optimised SNPs for both maximised allele frequency values in the form of matrix M whose columns correspond to the subjects of the population and the rows to the allele frequency values of each SNP for each subject the process comprises the selection of those SNPs that are biallelic, wherein subjects are represented as length haplotypes m formed by binary string {1,0}, wherein 1|0 and 0|1 are the allele frequency values for heterozygous SNPs and 0|0 and 1|1 are the allele frequency values for the homozygous SNPs; wherein this selection is made throughout the chromosomal region of interest the process comprises a stage of analysing the n candidate SNPs in the region and excluding the SNPs that meet any of the following conditions: SNPs with more than one alternative allele (non-biallelic SNPs); SNPs whose alleles are different from the change of a single nucleotide; SNPs that are homozygous in at least 99% of the population of interest; and uncommon SNPs, wherein the minor allele frequency is less than 1% a second SNP selection process wherein: all the SNP combinations are evaluated to obtain a minimum set t of tagSNPs from the matrix M obtained in the first SNP selection process the process comprises, firstly, that the SNPs of the matrix M of the block-region are organised in groups of high correlation based on the pairwise r2 criterion wherein the selection of tagSNPs within each group is made based on the linkage disequilibrium (LD) criterion, starting with k = 1 SNPs and studying all possible k-combinations, organising the SNPs within each group determine whether the embryo has a genetic disease by comparing the selected informative tagSNPs with a polymorphisms pattern of the embryo Mathematical concepts recited in claim 1 the process comprises a stage of maximising the situation in which one of the parents has the allele frequency value of a SNP in a heterozygous state, while the other parent has the allele frequency value of the SNP in a homozygous state, wherein the value of a SNP is informative and this is achieved through the maximization of the allele frequency value of two functions above a certain threshold value: MaxP:p-(3p2) + (4p3) – (2p4), HET rate: 2pq wherein p and q are, respectively, the allele frequencies of the reference and alternative alleles for each SNP in-silico validation process of the tagSNP panel obtained in the second process wherein the pairwise r2 criterion is calculated from the allele frequency calculated for the matrix M wherein the SNPs of different groups will present low correlation, wherein two SNPs will belong to the same group only when the pairwise r2 therebetween exceeds a certain threshold value set by the user a third process, wherein a genomic database is used where subjects are randomly chosen to perform 300 crosses, after which the number of tagSNPs that were informative of each crossing is counted and the average is provided as informative data of the informative power Dependent 3, 9, and 12 claims recite additional steps that either are directed to abstract ideas or further limit the judicial exceptions in independent claim 1 and as such, are further directed to abstract ideas. Hence, the claims explicitly recite numerous elements that individually, and in combination constitute abstract ideas. Claims 3, 9, and 12 include abstract steps: Claim 3: “the chromosomal region of interest is defined as any position that is located in a region ranging from two megabases above and two megabases below the gene or mutation under study” Claim 9: “if a SNP does not exceed the r2 criterion or LD it will be considered in one group only and taken as tagSNP by itself” Claim 12: “a first SNP selection process […]; a second SNP selection process […]; a third process […]” The abstract recited in the claims are evaluated under Broadest Reasonable Interpretation (BRI) and determined herein to each cover performance in the mind and by mathematical concepts because the steps involve nothing more than selecting SNPs based on calculated criteria. Because the claims do recite judicial exceptions, direction under (2A)(2) provides that the claims must be examined further to determine whether they integrate the abstract ideas into a practical application (MPEP 2106.04(d)). A claim can be said to integrate a judicial exception into a practical application when it applies, relies on, or uses the judicial exception in a manner that imposes a meaningful limit on the judicial exception. This is performed by analyzing the additional elements of the claim to determine if the abstract idea is integrated into a practical application (MPEP 2106.04(d).I; MPEP2106.05(a-h)). If the claim contains no additional elements beyond the abstract idea, the claim is said to fail to integrate the abstract idea into a practical application (MPEP 2106.04(d).III). Claim 1 recites the following additional elements: a biopsy discard the embryo with the genetic disease The step of a biopsy does not integrate the judicial exceptions into a practical application as it gathers the data on which the judicial exceptions are performed. Data gathering does not impose any meaningful limitation on the abstract idea, or how the abstract idea is performed. Data gathering steps are not sufficient to integrate an abstract idea into a practical application (MPEP 2106.05(g)). The step of discarding the defective embryo does not integrate all of the judicial exceptions into a practical application because the embryo is discarded if the embryo is determined to have a genetic disease based on the comparison of the selected informative tagSNPs. However, the first SNP selection process does not discuss selection of any tagSNPs, and thus this step does not integrate any of the judicial exceptions of the first SNP selection process into a practical application. The third process does discuss tagSNPs, but does not discuss selecting these tagSNPs, and thus the discarding of the embryo does not necessarily integrate these judicial exceptions into a practical application either. Claims 11 and 12 are directed to generic computer parts that perform or carry out the abstract ideas. Hence, these are mere instructions to apply the abstract idea using a computer, and therefore the claim does not integrate that abstract idea into a practical application. The courts have weighed in and consistently maintained that when, for example, a memory, display, processor, machine, etc. ... are recited so generically (i.e., no details are provided) that they represent no more than mere instructions to apply the judicial exception on a computer, and these limitations may be viewed as nothing more than generally linking the use of the judicial exception to the technological environment of a computer (see MPEP 2106.05(f)). None of these dependent claims recite additional elements, alone or in combination, which would integrate a judicial exception into a practical application. With respect to step (2B): Because the claims recite an abstract idea, and do not integrate that abstract idea into a practical application, the claims lack a specific inventive concept. The judicial exception alone cannot provide that inventive concept or practical application (MPEP 2106.05). Identifying whether the additional elements beyond the abstract idea amount to such an inventive concept requires considering the additional elements individually and in combination to determine if they provide significantly more than the judicial exception (MPEP 2106.05.A i-vi). With respect to the instant claims, the additional elements do not rise to the level of significantly more than the judicial exception. As set forth in the MPEP at 2106.05(d)(I), determinations of whether or not additional elements (or a combination of additional elements) may provide significantly more and/or an inventive concept rests in whether or not the additional elements (or combination of elements) represents well-understood, routine, conventional activity. Said assessment is made by a factual determination stemming from a conclusion that an element (or combination of elements) is widely prevalent or in common use in the relevant industry, which is determined by either a citation to an express statement in the specification or to a statement made by an applicant during prosecution that demonstrates a well-understood, routine or conventional nature of the additional element(s); a citation to one or more of the court decisions as discussed in MPEP 2106(d)(II) as noting the well-understood, routine, conventional nature of the additional element(s); a citation to a publication that demonstrates the well-understood, routine, conventional nature of the additional element(s); and/or a statement that the examiner is taking official notice with respect to the well-understood, routine, conventional nature of the additional element(s). With respect to claim 1: The additional elements of a biopsy and discarding the defective embryo do not rise to the level of significantly more than the judicial exception. As stated in the Specification, Preimplantation genetic diagnosis was developed in the 1980s and the process comprises biopsies of embryos and discarding defective embryos (pages 1 and 2). As such, it is recognized that these additional limitations are routine, well understood, and conventional in the art. These limitations do not improve the functioning of a computer, or comprise an improvement to any other technical field, they do not require or set forth a particular machine, they do not affect a transformation of matter, nor do they provide a non-conventional or unconventional step. As such, these limitations fail to rise to the level of significantly more. With respect to claim 11: The additional elements of at least one electronic device with a processor or processors and a memory, wherein the memory stores instructions that when executed by the processor or processor cause the electronic device to execute the method do not rise to the level of significantly more than the judicial exception. With respect to the processor and memory, as exemplified in the MPEP at 2106.05(f) with reference to Alice Corp. 573 US at 223, 110 USPQ2d at 1983 “claims that amount to nothing more than an instruction to apply the abstract idea using a generic computer do not render an abstract idea eligible”. Therefore, the programmed computer constitutes no more than a general link to a technological environment, which is insufficient to constitute an inventive concept that would render the claims significantly more than an abstract idea (see MPEP 2105(b)I-III). With respect to claim 12: The additional elements of a computer readable medium with instructions configured to be executed by one or more processor that make the electronic device of the kit of claim 11 perform a method do not rise to the level of significantly more than the judicial exception. With respect to the computer-readable medium and processor, as exemplified in the MPEP at 2106.05(f) with reference to Alice Corp. 573 US at 223, 110 USPQ2d at 1983 “claims that amount to nothing more than an instruction to apply the abstract idea using a generic computer do not render an abstract idea eligible”. Therefore, the programmed computer constitutes no more than a general link to a technological environment, which is insufficient to constitute an inventive concept that would render the claims significantly more than an abstract idea (see MPEP 2105(b)I-III). In combination, the computer elements that implement the judicial exceptions fail to rise to the level of significantly more. No non-routine element has clearly been identified. The claims have all been examined to identify the presence of one or more judicial exceptions. Each additional limitation in the claims has been addressed, alone and in combination, to determine whether the additional limitations integrate the judicial exception into a practical application. Each additional limitation in the claims has been addressed, alone and in combination, to determine whether those additional limitations provide an inventive concept which provides significantly more than those exceptions. Individually, the limitations of the claims and the claims as a whole have been found to not meet the eligibility requirements. Response to Arguments Applicant states that “Applicant has amended claims 1 and 12 to recite, in part: ‘determine whether the embryo has a genetic disease by comparing the selected informative tagSNPs with a polymorphisms pattern of the embryo and then discard the embryo with the genetic disease.’ The Applicant respectfully submits the amendments herein integrate the judicial exception into a practical application.” It is respectfully submitted that this is not persuasive. The step of discarding the defective embryo does not integrate all of the judicial exceptions into a practical application because the embryo is discarded if the embryo is determined to have a genetic disease based on the comparison of the selected informative tagSNPs. However, the first SNP selection process does not discuss selection of any tagSNPs, and thus this step does not integrate any of the judicial exceptions of the first SNP selection process into a practical application. The third process does discuss tagSNPs, but does not discuss selecting these tagSNPs, and thus the discarding of the embryo does not necessarily integrate these judicial exceptions into a practical application either. Therefore, the rejection under 35 USC 101 is maintained. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Emilie A Smith whose telephone number is (571)272-7543. The examiner can normally be reached 9am - 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Larry D Riggs can be reached at (571)270-3062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /E.A.S./Examiner, Art Unit 1686 /LARRY D RIGGS II/Supervisory Patent Examiner, Art Unit 1686
Read full office action

Prosecution Timeline

Jan 21, 2021
Application Filed
Mar 22, 2024
Non-Final Rejection — §101
Jun 28, 2024
Response Filed
Oct 15, 2024
Final Rejection — §101
Jan 24, 2025
Examiner Interview Summary
Jan 24, 2025
Applicant Interview (Telephonic)
Mar 10, 2025
Request for Continued Examination
Mar 16, 2025
Response after Non-Final Action
Aug 05, 2025
Non-Final Rejection — §101
Nov 06, 2025
Applicant Interview (Telephonic)
Nov 17, 2025
Examiner Interview Summary
Dec 12, 2025
Response Filed
Jan 22, 2026
Final Rejection — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12603150
CALCULATING CELL-TYPE RNA PROFILES FOR DIAGNOSIS AND TREATMENT
2y 5m to grant Granted Apr 14, 2026
Patent 12602520
MACHINE-LEARNING VIRTUALIZATION-ENABLED HARVESTING
2y 5m to grant Granted Apr 14, 2026
Patent 12586661
HARDWARE ACCELERATED K-MER GRAPH GENERATION
2y 5m to grant Granted Mar 24, 2026
Patent 12518850
SYSTEMS AND METHODS FOR FULLY AUTOMATED PROTEIN ENGINEERING
2y 5m to grant Granted Jan 06, 2026
Patent 12514640
SYSTEMS AND METHODS FOR VISUALLY GUIDING BONE REMOVAL DURING A SURGICAL PROCEDURE ON A JOINT
2y 5m to grant Granted Jan 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
52%
Grant Probability
87%
With Interview (+35.4%)
4y 8m
Median Time to Grant
High
PTA Risk
Based on 68 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month